Live Breaking News & Updates on பிரியா கிருஷ்ணசாமி|Page 4
Stay updated with breaking news from பிரியா கிருஷ்ணசாமி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MUMBAI/ PUNE: In the largest study done so far in India to understand why people got Covid-19 despite taking one or two vaccine shots, scientists from the Pune-based National Institute of Virology (NIV) found a simple answer: B.1.617.2, that is better known as the Delta variant. The Delta variant was found in 87% of the 677 throat and nasal swabs of Covid-19 patients from 17 states and union territories. While 592 of these patients had taken two doses, 85 had taken only one dose before getting infected with the SARS2 virus. The genomic analysis showed the Delta variant’s presence in the majority of the samples, but there also were other variants such as Alpha, Kappa, Delta AY.1 (known as the Delta-plus variant in samples from Madhya Pradesh and Rajasthan) and Delta AY.2. The study, led by director Dr Priya Abraham and senior scientist Dr Pragya Yadav, also found that less than 10% of the 677 patients needed hospitalisation, alluding to the vaccine’s effectiveness in ....
Representative image MUMBAI/PUNE: In the largest study done so far in India to understand why people got Covid-19 despite taking one or two vaccine shots, scientists from Pune-based National Institute of Virology (NIV) found a simple answer: B.1.617.2 (Delta variant). Genomic analysis found Delta in 87% of the 677 throat and nasal swabs of patients from 17 states and UTs. While 592 of them had taken two doses, 85 had taken only one dose before getting infected with the SARS2 virus. The study, led by director Dr Priya Abraham and senior scientists Dr Pragya Yadav, also found that less than 10% of the 677 patients needed hospitalisation, alluding to the vaccine’s effectiveness in preventing a severe infection. ....
‘కొవాగ్జిన్’ టీకా సామర్థ్యం 77.8 శాతం డెల్టా వేరియంట్ నుంచి 65.2 శాతం రక్షణ మూడో దశ క్లినికల్ పరీక్షల తుది విశ్లేషణ ఈనాడు, హైదరాబాద్: కొవిడ్-19కి భారత్ బయోటెక్ ఇంటర్నేషనల్ అభివృద్ధి చేసిన ‘కొవాగ్జిన్’ టీకాకు 77.8 శాతం సమర్థత ఉన్నట్లు మూడో దశ క్లినికల్ పరీక్షల తుది విశ్లేషణలో నిర్ధారణ అయింది. ఈ టీకా తీసుకుంటే ప్రాణాంతక కరోనా వైరస్- డెల్టా వేరియంట్ నుంచి 65.2 శాత ....
Phase-3 Trials Show Covaxin 93.4 Per Cent Effective Against Severe COVID-19 But Supply Marred By Delay In Manufacturing swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.
Covaxin third phase clinical trials results out, 77.8 per cent effective against Covid-19 Covaxin has also been found to be 65.2 percent effective against the dreaded Delta variant of Coronavirus, which is becoming the dominant strain of the virus across the world. Share Via Email | A+A A- By Express News Service HYDERABAD: Covaxin, the Covid-19 vaccine developed by Hyderabad-based vaccine maker Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been found to be 77.8 percent effective in the Phase-III clinical trials. Also, Covaxin has been found to be 93.4% effective against severe symptomatic form of Covid-19 and 63.6 percent effective against asymptomatic Covid-19. ....